Westborough

Underwriters of Westborough-based Virtusa Corp. have exercised their option to purchase an additional 345,000 shares of company stock.

Virtusa Corp. of Westborough has bought a Swedish consulting and IT service provider in a deal that could wind up being worth $24 million.

RXi Pharmaceuticals of Westborough has signed a five-year lease for 7,581 square feet of office and laboratory space in Marlborough, according to a filing Friday with the U.S. Securities and Exchange Commission.

Local transportation and planning leaders celebrated the official launch of the new Worcester Regional Transit Authority (WRTA) business shuttle service in Westborough with a ribbon cutting ceremony at the MBTA station on Smith Parkway and Fisher Street Monday morning.

Almost Family, Inc., a home health agency with operations in Westborough, announced it has completed the acquisition of Nashville-based SunCrest HealthCare, a home health agency with 75 locations throughout the U.S.

Overnight delivery by air may be quick, but the majority of U.S. goods will likely be shipped by ground — by rail and road — for the foreseeable future, industry experts say.

Westborough's eClinicalWorks has positioned itself as a market leader in health care IT by tailoring innovative products to the changing market. Today, that means reaching out to health care consumers, who are expected to become involved in choosing where to seek treatment as federal health care reform ushers in a new, value-based system in which more people will have health insurance, and pressure from payers to curb costs mounts.

Westborough-based information technology firm eClinicalWorks said it's investing another $50 million in its mobile health business unit, allowing the company to hire an additional 100 software developers.

SimpliVity Corp., a Westborough-based IT startup, said it has secured $58 million in Series C financing to support continued growth.

Westborough-based RXi Pharmaceuticals has signed an agreement with a British company to distribute RXi's clinical-stage dermal scarring drug in the European Union ahead of regulatory approval. RXi said in a statement that Ethicor Ltd., a London-based specialty pharmaceuticals company that distributes unlicensed medicines used for unmet clinical needs, now has the distribution rights to RXI-109 in the European Union with the potential to distribute the drug to other parts of the world before the product is registered in the countries covered by the agreement.